<DOC>
	<DOCNO>NCT02252172</DOCNO>
	<brief_summary>The purpose study compare efficacy daratumumab combination lenalidomide dexamethasone lenalidomide dexamethasone term progression-free survival ( PFS ) participants newly diagnose multiple myeloma ( blood cancer plasma cell ) candidate high dose chemotherapy ( treatment disease , usually cancer , chemical agent ) autologous stem cell transplant ( ASCT ) .</brief_summary>
	<brief_title>Study Comparing Daratumumab , Lenalidomide , Dexamethasone With Lenalidomide Dexamethasone Participants With Previously Untreated Multiple Myeloma</brief_title>
	<detailed_description>This Phase 3 , randomize ( study drug assign chance ) , open-label ( participant researcher aware treatment , participant receive ) , active-controlled ( study experimental treatment procedure compare standard treatment procedure ) , parallel-group ( group participant treat time ) , multicenter ( one hospital medical school team work medical research study ) study participant newly diagnose multiple myeloma candidate high dose chemotherapy ASCT . All eligible participant randomly assign receive either daratumumab combination lenalidomide dexamethasone ( DRd ) lenalidomide dexamethasone ( Rd ) . Daratumumab ( 16 milligram per kilogram [ mg/kg ] ) administer weekly first 8 week ( Cycles 1 2 ) treatment every week 16 week ( Cycles 3 6 ) , every 4 week ( Cycle 7 beyond ) progression disease unacceptable toxicity . Lenalidomide administer dose 25 mg orally Days 1 21 28-day cycle , dexamethasone administer dose 40 mg week treatment arm . Participants DRd arm receive lenalidomide/dexamethasone maximum 2 year ( participant continue receive dexamethasone premedication daratumumab administration even lenalidomide/dexamethasone treatment discontinue ) ; Rd arm continue lenalidomide/dexamethasone disease progression unacceptable toxicity.The study consist 3 phase : Screening Phase ( within 21 day prior first dose administration Day 1 ) , Treatment Phase ( Day 1 discontinuation study treatment ) , Follow-up Phase ( discontinuation study treatment death , lose follow , consent withdrawal , study end , whichever occur first ) . The maximum duration study 5 year last participant randomize . Efficacy primarily evaluate PFS . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant must document multiple myeloma satisfy CRAB ( calcium elevation , renal insufficiency , anemia bone abnormality ) criterion , monoclonal plasma cell bone marrow great equal ( &gt; = ) 10 percent ( % ) presence biopsy proven plasmacytoma measurable disease define follow : ( ) immunoglobulin ( Ig ) G myeloma ( serum monoclonal paraprotein [ Mprotein ] level &gt; =1.0 gram/deciliter [ g/dL ] urine Mprotein level &gt; =200 milligram [ mg ] /24 hour [ hr ] ; ( b ) IgA , IgM , IgD , IgE multiple myeloma ( serum Mprotein level &gt; =0.5 g/dL urine Mprotein level &gt; =200 mg/24 hr ) ; ( c ) light chain multiple myeloma without measurable disease serum urine ( serum immunoglobulin free light chain &gt; =10 mg/dL abnormal serum immunoglobulin kappa lambda free light chain ratio ) Participant must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Participants newly diagnose consider highdose chemotherapy due : age &gt; =65 year ; participant less ( &lt; ) 65 year presence important comorbid condition ( ) likely negative impact tolerability high dose chemotherapy stem cell transplantation . Sponsor review approval participant 65 year age require randomization Women childbearing potential must commit either abstain continuously sexual intercourse use 2 method reliable birth control simultaneously deem appropriate Investigator . Contraception must begin 4 week prior dose must continue 3 month last dose daratumumab Man , sexually active woman childbearing potential potential must agree use latex synthetic condom , even successful vasectomy , must agree use adequate contraception method deem appropriate Investigator , must also agree donate sperm study 4 week last dose lenalidomide 4 month last dose daratumumab Participant diagnosis primary amyloidosis , monoclonal gammopathy undetermined significance ( presence serum Mprotein &lt; 3 g/dL ; absence lytic bone lesion , anemia , hypercalcemia , renal insufficiency relate Mprotein ) , smolder multiple myeloma ( asymptomatic multiple myeloma absence relate organ tissue impairment end organ damage ) Participant diagnosis Waldenstr√∂m 's disease , condition IgM M protein present absence clonal plasma cell infiltration lytic bone lesion Participant history malignancy ( multiple myeloma ) within 5 year date randomization ( exception squamous basal cell carcinoma skin carcinoma situ cervix , malignancy opinion Investigator , concurrence Sponsor 's medical monitor , consider cure minimal risk recurrence within 5 year ) Participant prior current systemic therapy SCT multiple myeloma , exception emergency use short course ( equivalent dexamethasone 40 mg/day 4 day ) corticosteroids treatment Participant radiation therapy within 14 day randomization Participant know chronic obstructive pulmonary disease ( COPD ) ( define force expiratory volume 1 second [ FEV1 ] &lt; 50 % predict normal ) , persistent asthma , history asthma within last 2 year ( control intermittent asthma control mild persistent asthma allow ) Participants know suspected COPD must FEV1 test Screening Participant know seropositive human immunodeficiency virus ( HIV ) hepatitis B ( define positive test hepatitis B surface antigen [ HBsAg ] antibodies hepatitis B surface core antigens [ antiHBs antiHBc , respectively ] ) hepatitis C ( antiHCV antibody positive HCVribonucleic acid [ RNA ] quantitation positive )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>JNJ-54767414</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>